Tags : Technologies

GSK Signs a Five Years Collaboration with Lyell to Develop

Shots: Lyell to apply its technologies to strengthen GSK’s cell therapy pipeline including GSK3377794 targeting the NY-ESO-1 antigen expressed along multiple cancer plus an approach to counter T cell exhaustion while increasing probability for delivering cancer therapies The focus of the agreement is to combine the GSK’s strong cell and gene therapy programmes with Lyell’s […]Read More

Merck to Acquire Immune Design for its Technologies for $300M

Shots: Merck acquires Immune Design, in all stock transaction for $5.85/share in cash making total deal value ~ $300M. The transaction is expected to close in Q2’19 The focus of the agreement is to develop and commercialize immune vaccines using Immune Design’s in vivo technologies i.e GLAAS and ZVex against cancer and infectious diseases GLA […]Read More